ETF Copies Hedgies,...
Health Care: Drugs
ImmunoCellular Therapeutics Limited (IMUC: AMEX)
$2.54 0.00 | 0.00%
05/21/13 - 04:01 PM ET
Company Balance Sheet
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 26.22M | 6.65M | 5.32M | 331.35K |
| Receivables | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 714.51K | 91.29K | 24.03K | 21.90K |
| Total Current Assets | 26.93M | 6.74M | 5.34M | 1.43M |
| Property, Plant & Equipment, Gross | 151.57K | 105.86K | 12.37K | 5.43K |
| Accumulated Depreciation & Depletion | 75.28K | 29.46K | 0.00 | 0.00 |
| Property, Plant & Equipment, Net | 76.29K | 76.40K | 12.37K | 5.43K |
| Intangibles | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Assets | 11.74K | 329.90K | 8.97K | 38.13K |
| Total Non-Current Assets | 88.02K | 406.30K | 21.34K | 43.56K |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 27.02M | 7.15M | 5.37M | 1.47M |
| Accounts Payable | 732.85K | 1.32M | 171.06K | 225.60K |
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Liabilities | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Liabilities | 1.10M | 1.76M | 447.45K | 375.72K |
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Liabilities | 2.85M | 2.16M | 2.58M | 0.00 |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Liabilities | 2.85M | 2.16M | 2.58M | 0.00 |
| Total Liabilities | 3.95M | 3.92M | 3.03M | 375.72K |
| Preferred Stock Equity | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Equity | 23.07M | 3.23M | 2.34M | 1.10M |
| Common Par | 5.15K | 2.86K | 2.22K | 14.87K |
| Additional Paid In Capital | 66.23M | 31.90M | 25.34M | 15.85M |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | -43.17M | -28.67M | -22.95M | -14.71M |
| Treasury Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Equity Adjustments | 0.00 | 0.00 | -54.28K | -52.67K |
| Total Capitalization | 23.07M | 3.23M | 2.34M | 1.10M |
| Total Equity | 23.07M | 3.23M | 2.34M | 1.10M |
| Total Liabilities & Stock Equity | 27.02M | 7.15M | 5.37M | 1.47M |
| Total Common Shares Outstanding | 51.50M | 28.61M | 22.21M | 14.87M |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic Weighted Shares Outstanding | 41.80M | 27.45M | 19.19M | 13.72M |
| Diluted Weighted Shares Outstanding | 41.80M | 27.45M | 19.19M | 13.72M |
| Number of Employees | 5 | 4 | 3 | 3 |
| Number of Part-Time Employees | 2 | 0 | 0 | 2 |
Portfolios with IMUC
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- UserBiotech88
- ContributorStocks Under-$10 Setting Up...
Latest IMUC Headlines from TheStreet
- IMUC July Options Begin Trading 05.20.13 | 04:05 pm
- Biotech Stock Mailbag: Celldex, TG Therapeutics, Sarepta 03.08.13 | 06:03 am
- Biotech Stock Mailbag: Dynavax, ImmunoCellular, Celldex and Medgenics 02.08.13 | 06:02 am
- 3 Stocks Under $5 Making Big Moves 02.05.13 | 02:02 pm
- The Twitterverse's Biotech Stock Picks for 2013 01.02.13 | 08:01 am
- Biotech Stock Mailbag: Keryx, Amarin, ImmunoCellular 06.08.12 | 09:06 am
- 5 Stocks Under $10 Set to Soar 06.01.12 | 11:06 am
- 5 Stocks Under $10 Set to Soar 12.31.69 | 07:12 pm
Press Releases for IMUC
- ImmunoCellular Therapeutics To Present At Future Leaders Conference On April 5th - Business Wire 03.28.13 | 06:03 am
- ImmunoCellular Therapeutics To Present At ROTH Conference On March 18th - Business Wire 03.11.13 | 04:03 pm
- ImmunoCellular Therapeutics Announces Fourth Quarter And Full Year 2012 Financial Results - Business Wire 03.05.13 | 04:03 pm
- ImmunoCellular Therapeutics Announces Issuance Of Key Patent For ICT-121 Cancer Vaccine - Business Wire 03.04.13 | 06:03 am
- ImmunoCellular Therapeutics To Report Financial Results For The Fourth Quarter And Full Year 2012 On March 5, 2013 - Business Wire 02.26.13 | 06:02 am
- ImmunoCellular Therapeutics To Present At BIO CEO & Investor Conference On February 11th - Business Wire 02.04.13 | 04:02 pm
- ImmunoCellular Therapeutics’ Investigational New Drug (IND) Application For ICT-140 Allowed By The FDA - Business Wire 01.29.13 | 06:01 am
- ImmunoCellular Therapeutics Provides Update On Corporate Milestones - Business Wire 01.07.13 | 06:01 am
- ImmunoCellular Therapeutics Appoints Gary S. Titus To Its Board Of Directors - Business Wire 01.02.13 | 06:01 am
- ImmunoCellular Therapeutics Appoints Andrew Gengos As Chief Executive Officer - Business Wire 12.03.12 | 04:12 pm
Partner Headlines for IMUC
- ImmunoCellular Update Adds Clarity And Further Validates Investment Thesis - Seeking Alpha 03.07.13 | 09:03 am
- ImmunoCellular Therapeutics: An Opportunity For Great Upside Potential - Seeking Alpha 11.21.12 | 08:11 am
- ImmunoCellular Therapeutics Announces Pricing of its Previously Announced Public Offering of Common Stock and Warrants - Benzinga 10.18.12 | 09:10 am
- A Gold Mine In Biotechnology: The Companies Poised To Benefit - Seeking Alpha 09.04.12 | 09:09 am
- Reassessing & Continuing To Monitor Portfolios For Success - Seeking Alpha 07.30.12 | 09:07 am
- ImmunoCellular Provides Update on Phase II Clinical Trial of ICT-107 for Treatment of Glioblastoma - Benzinga 07.02.12 | 09:07 am
- MLV & Co Reiterates Buy, $4.50 PT on ImmunoCellular Therapeutics on Move to NYSE - Benzinga 05.25.12 | 12:05 pm
- Zacks Bull and Bear of the Day Highlights: ImmunoCellular, Willis Group Holdings, Encana, Exxon Mobil and Cenovus Energy - Press Releases - Zacks 02.21.12 | 09:02 am
- ImmunoCellular (IMUC) - Bull of the Day - Zacks 02.21.12 | 01:02 am
- Biotechs to Watch at the 2012 San Francisco Healthcare Confrences - Analyst Blog - Zacks 01.09.12 | 07:01 am
